Summary: Recursion announced the completion of BioHive-2, a new NVIDIA DGX SuperPOD AI supercomputer, resulting in four times faster speeds than their original supercomputer in benchmark performance tests. This supercomputer will accelerate their use of a growing dataset for training new AI models and advancing drug discovery efforts.
Full articleSummary: Lexicon Pharmaceuticals, Inc. announced its participation in the Bank of America Securities Healthcare Conference 2024 where its president and chief financial officer will make a company presentation. The simultaneous webcast will be available on the company's website.
Full articleSummary: Nvidia owns a 3.4% stake in Recursion Pharmaceuticals, a biotech company using AI for drug discovery. Recursion aims to improve the drug discovery process by reducing costs and moving faster. The company already has partnerships with Roche and Bayer.
Full articleSummary: Nvidia disclosed its portfolio of AI stocks surpassing $100 million, with a concentration on ARM Holdings and a 3.4% stake in Recursion Pharmaceuticals. Recursion aims to improve drug discovery using AI and big data, with partnerships in place with Roche and Bayer.
Full articleSummary: Nvidia has over $100 million in portfolio of AI stocks, with a significant investment in ARM Holdings and a 3.4% stake in Recursion Pharmaceuticals. Recursion focuses on using AI to improve drug discovery process, with potential to become Nvidia's biggest investment if successful. However, investing in Recursion is considered a risky bet due to its high R&D expenses and ongoing cash burn.
Full articleSummary: Nvidia has made a sizable investment in AI stocks, with Recursion Pharmaceuticals being one of its key holdings as they use AI for drug discovery process.
Full articleSummary: Multiple companies have had their stock target prices adjusted by various analysts, including Jefferies, Bernstein, and Raymond James.
Full articleSummary: The market correction is expected to see a bounce to the upside before further declines, with IBM's earnings report anticipated to lead to a decline in the stock price, while Xerox's report is expected to lift the share price.
Full article